Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

TAK vs UTHR: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

TAK Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 6–4 Matrix Metrics)

TAK Overall Winner 6-Pillar Tally: TAK 4 – 2 UTHR Matrix Metrics: TAK 6 – 4 UTHR

As of Nov 16, 2026, Takeda Pharmaceutical Company Limited (TAK) is the stronger overall head-to-head candidate over United Therapeutics Corp (UTHR) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). TAK carries a Unified Composite Score of 47.7/100 (HOLD) at $21.61 (12.7x Forward P/E, 16.6% operating margin), whereas UTHR carries 43.9/100 (HOLD) at $584.19 (18.8x Forward P/E, 39.4% operating margin).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About TAK vs UTHR
TAK NYSE Head-to-Head Winner
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Pharmaceutical Preparations
$21.61
+0.86% 1D
Market Cap $67.5B
TTM Revenue $25.7B
Forward P/E 12.7x
Beta / 30D Vol -0.02β · 22% Vol
Unified Composite Score
47.7 / 100 HOLD
Tech 42.0 Fund 43.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (5.9% over 20 days), RSI 73
RSI-14: 73.1 · SMA20: $20.72 · SMA50: $19.46
UTHR NASDAQ
United Therapeutics Corp
Pharmaceutical Preparations
$584.19
-1.18% 1D
Market Cap $25.3B
TTM Revenue $3.19B
Forward P/E 18.8x
Beta / 30D Vol 0.34β · 34% Vol
Unified Composite Score
43.9 / 100 HOLD
Tech 31.0 Fund 48.0 Flow 68.0 Mom 31.1
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (5.8% over 20 days), RSI 57
RSI-14: 57.1 · SMA20: $586.34 · SMA50: $544.64

6-Pillar Scorecard Institutional Category Breakdown (TAK 4 – 2 UTHR)

Columns: Metric · TAK · UTHR
1. Valuation Multiples TAK
Forward P/E 12.7x 18.8x
Trailing P/E N/M 22.4x
PEG Ratio 0.47x 2.22x
EV / Revenue 2.6x 7.9x
2. Growth & Scale TAK
Revenue Growth (YoY) +6.7% +4.1%
Earnings Growth (YoY) -9.8% -20.3%
TTM Revenue (USD) $25.7B $3.19B
Market Cap $67.5B $25.3B
3. Profitability & Quality UTHR
Gross Margin 64.8% 86.3%
Operating Margin 16.6% 39.4%
Net Profit Margin 0.9% 38.6%
Return on Equity (ROE) 0.6% 19.1%
4. Balance Sheet & Cash Flow TAK
Cash Generation (TTM) $7.48B EBITDA $867M
Cash Flow Margin 29.1% EBITDA Mgn 27.2%
Net Cash / Leverage $14.68 Book/Sh · 0.6% ROE $148.08 Book/Sh · 19.1% ROE
Dividend Yield 2.92% None (0.00%)
5. Options & Positioning UTHR
Options Structure Phase UNCLASSIFIED SURGE
Current IV / %ile 22.4% (5th %ile) 31.8% (6th %ile)
Put/Call OI Skew Thin ADR Chain 0.75x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markup ACCUMULATION · Markup
6. R&D & Supply-Chain Moat TAK
OpEx & R&D Intensity 48.2% of Rev ($12.4B) 46.9% of Rev ($1.49B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat High-Margin Pricing Power Moat
Supply-Chain Role Drug Manufacturers - Specialty & Generic Operator Drug Manufacturers - Specialty & Generic Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: TAK (6) vs UTHR (4)
Institutional Metric TAK UTHR Criterion Row Edge
Market Capitalization
Scale
$67.5B $25.3B Larger Scale TAK
Trailing P/E Ratio
Valuation
N/M 22.4x Lower Multiple UTHR
Forward P/E Ratio
Valuation
12.7x 18.8x Lower Multiple TAK
Revenue Growth (YoY)
Growth
+6.7% +4.1% Higher Growth TAK
Operating Margin (TTM)
Profitability
16.6% 39.4% Higher Margin UTHR
Net Profit Margin
Profitability
0.9% 38.6% Higher Margin UTHR
Return on Equity (ROE)
Capital Efficiency
0.6% 19.1% Higher ROE UTHR
52-Week Range Position
Momentum
97% ($14–$22) 81% ($456–$614) Stronger Trend TAK
Beta / 30D Volatility
Risk Regime
-0.02β · 22% Vol 0.34β · 34% Vol Lower Realized Risk TAK
Unified Institutional Score
Composite Signal
47.7 / 100 (HOLD) 43.9 / 100 (HOLD) Higher Composite TAK
Trailing 12M Revenue (USD)
Operating Scale
$25.7B $3.19B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
64.8% 86.3% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
0.47x PEG · 2.6x EV/Rev 2.22x PEG · 7.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$7.48B EBITDA ($14.68 Book/Sh · 0.6% ROE) $867M ($148.08 Book/Sh · 19.1% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon TAK +0.31 pp
TAK: +9.89% · UTHR: +9.58%
3M Horizon TAK +7.03 pp
TAK: +19.75% · UTHR: +12.72%
6M Horizon TAK +27.42 pp
TAK: +30.45% · UTHR: +3.03%
1Y Horizon TAK +25.42 pp
TAK: +51.79% · UTHR: +26.37%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on TAK vs UTHR. Trailing 12-month operating profitability (TAK 16.6% vs UTHR 39.4%) and valuation multiples (TAK 12.7x vs UTHR 18.8x Forward P/E) are benchmarked directly in Pillar 4 below.

TAK ADR TTM Benchmark FX-Normalized USD
TTM Revenue$25.7B
Gross Margin64.8%
Op. Margin16.6%
ROE / Fwd P/E0.6% · 12.7x
UTHR ADR TTM Benchmark FX-Normalized USD
TTM Revenue$3.19B
Gross Margin86.3%
Op. Margin39.4%
ROE / Fwd P/E19.1% · 18.8x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
TAK UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 22.4%
IV Percentile 5th %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact TAK Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
UTHR SURGE
8d in phase · OBV ACCUMULATION
Current IV 31.8%
IV Percentile 6th %ile
Put/Call OI Skew 0.75x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow ACCUMULATION
Exact UTHR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
TAK Moat Profile Scale & Operating Efficiency Moat
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $67.5B market capitalization and 16.6% operating margin.
OpEx & R&D Reinvestment 48.2% of Rev ($12.4B)
90D Engineering Disclosures 0 Published
UTHR Moat Profile High-Margin Pricing Power Moat
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $25.3B market capitalization and 39.4% operating margin.
OpEx & R&D Reinvestment 46.9% of Rev ($1.49B)
90D Engineering Disclosures 0 Published

Investor FAQ TAK vs UTHR Key Questions & Quantitative Answers

As of Nov 16, 2026, Takeda Pharmaceutical Company Limited (TAK) is the stronger overall head-to-head candidate over United Therapeutics Corp (UTHR) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). TAK carries a Unified Composite Score of 47.7/100 (HOLD) at $21.61 (12.7x Forward P/E, 16.6% operating margin), whereas UTHR carries 43.9/100 (HOLD) at $584.19 (18.8x Forward P/E, 39.4% operating margin). Technically, TAK sits in a Markup phase (RSI 73.1, UNCLASSIFIED options structure) and UTHR sits in a Markup phase (RSI 57.1, SURGE options structure).

TAK leads the Growth & Scale pillar: TAK posts +6.7% YoY revenue growth and -9.8% YoY earnings growth on $25.7B TTM revenue (64.8% gross margin, 16.6% operating margin), compared with UTHR at +4.1% YoY revenue growth and -20.3% YoY earnings growth on $3.19B TTM revenue (86.3% gross margin, 39.4% operating margin). On trailing 12-month operating scale, TAK generates $25.7B in USD-normalized revenue versus $3.19B for UTHR. In operating R&D and SG&A reinvestment, TAK deploys 48.2% of Rev ($12.4B) (0 90-day corporate R&D disclosures) versus 46.9% of Rev ($1.49B) (0 disclosures) for UTHR.

TAK screens cheaper on headline valuation multiples. TAK trades at 12.7x Forward P/E, N/M Trailing P/E, 0.47x PEG, and 2.6x EV/Revenue (29.1% EBITDA margin), whereas UTHR trades at 18.8x Forward P/E, 22.4x Trailing P/E, 2.22x PEG, and 7.9x EV/Revenue (27.2% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against TAK (0.6% ROE) versus UTHR (19.1% ROE) capital efficiency.

In options market volatility and institutional positioning, TAK carries 22.4% implied volatility (5th %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.02β · 22% Vol realized risk). By comparison, UTHR carries 31.8% implied volatility (6th %ile, Compressed (<25th %ile)), a 0.75x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a SURGE options structure phase (0.34β · 34% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) Research Suite

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.